Fenoglide (LCP-FenoChol)

General Information

Company	Veloxis Pharmaceuticals A/S
Description	Solid solution MeltDose formulation of low-dose fenofibrate
Molecular Target
Mechanism of Action

Latest Stage of Development	Marketed
Indication	Dyslipidemia
Partner	Santarus Inc.; Shore Therapeutics Inc.

Product Details

Archive Items are loading